Hudson Bay Capital Management LP Sells 5,000 Shares of Merck & Co., Inc. (NYSE:MRK)

Hudson Bay Capital Management LP lowered its stake in Merck & Co., Inc. (NYSE:MRK) by 25.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,000 shares of the company’s stock after selling 5,000 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Merck & Co., Inc. were worth $1,227,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of MRK. Norges Bank bought a new stake in Merck & Co., Inc. during the 4th quarter valued at approximately $2,250,767,000. Nuveen Asset Management LLC boosted its holdings in shares of Merck & Co., Inc. by 20.4% in the 4th quarter. Nuveen Asset Management LLC now owns 24,251,965 shares of the company’s stock worth $1,983,811,000 after purchasing an additional 4,112,158 shares during the period. California Public Employees Retirement System boosted its holdings in shares of Merck & Co., Inc. by 31.6% in the 4th quarter. California Public Employees Retirement System now owns 13,542,412 shares of the company’s stock worth $1,107,769,000 after purchasing an additional 3,252,367 shares during the period. Morgan Stanley boosted its holdings in shares of Merck & Co., Inc. by 16.7% in the 4th quarter. Morgan Stanley now owns 22,569,366 shares of the company’s stock worth $1,846,174,000 after purchasing an additional 3,221,509 shares during the period. Finally, Amundi Pioneer Asset Management Inc. boosted its holdings in shares of Merck & Co., Inc. by 24.5% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 11,699,450 shares of the company’s stock worth $957,001,000 after purchasing an additional 2,305,113 shares during the period. 72.86% of the stock is currently owned by hedge funds and other institutional investors.

Shares of MRK stock opened at $76.12 on Thursday. Merck & Co., Inc. has a 1-year low of $71.71 and a 1-year high of $87.80. The stock’s fifty day moving average price is $75.36 and its 200 day moving average price is $79.05. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.30 and a quick ratio of 1.00. The company has a market cap of $192.61 billion, a price-to-earnings ratio of 16.84, a price-to-earnings-growth ratio of 1.89 and a beta of 0.43.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Wednesday, February 3rd. The company reported $1.32 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.38 by ($0.06). Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. The business had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.65 billion. During the same quarter last year, the firm earned $1.16 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 5.9 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 7th. Shareholders of record on Monday, March 15th were paid a dividend of $0.65 per share. The ex-dividend date was Friday, March 12th. This represents a $2.60 annualized dividend and a yield of 3.42%. Merck & Co., Inc.’s payout ratio is presently 50.10%.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Merck & Co., Inc. in a research note on Friday, February 5th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $95.92.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as and vaccine products.

Recommended Story: Trading Halts Explained

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.